Curative effect of Guishao Liujunzi decoction combined with entecavir tablets in the treatment of liver cirrhosis with hepatitis B
10.3760/cma.j.issn.1008-6706.2018.17.013
- VernacularTitle: 归芍六君子汤联合恩替卡韦片治疗乙型肝炎肝硬化的疗效观察
- Author:
Wen ZHOU
1
,
2
Author Information
1. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
2. (Work for Department of Gastroenterology of Dongyang Guangfu Hospital)
- Publication Type:Journal Article
- Keywords:
Guishao Liujunzi Decoction;
Entecavir;
Hepatitis B;
Cirrhosis;
Curative effect
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(17):2228-2232
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the clinical effect of Guishao Liujunzi decoction combined with entecavir tablets in the treatment of liver cirrhosis with hepatitis B, and to provide reference for the clinical treatment.
Methods:From May 2012 to January 2015, 80 patients with hepatitis B-induced liver cirrhosis treated in Dongyang Guangfu Hospital were selected, and they were divided into control group(n=40) and observation group(n=40) according to the different method.The control group was given entecavir tablets, while the observation group was given Guishao Liujunzi decoction on this basis.The TCM symptom scores and levels of alanine aminotransferase(ALT), aspartate aminotransferase(AST), gamma glutamyl transferase(GGT), total bilirubin(TBil), prothrombin time(PT), hepatitis B virus deoxyribonucleic acid(HBV-DNA) of the two groups before treatment and 3 months, 6 months and 12 months after treatment were compared.
Results:The TCM symptom scores of the control group at 3 months, 6 months and 12 months after treatment were (12.68±1.82)points, (12.07±1.74)points, (11.38±1.63)points, respectively, which were higher than that before treatment[(14.30±1.48)points, t=4.368, 6.174, 8.388, all P<0.05]. The TCM symptom scores of the observation group at 3 months, 6 months and 12 months after treatment were (11.25±1.63)points, (10.40±1.82)points, (9.81±1.47)points, respectively, which were higher than before treatment[(14.59±1.61)points, t=9.137, 10.828, 13.780, all P<0.05]. The TCM symptom scores of the observation group at 3 months, 6 months and 12 months after treatment were significantly lower than those of the control group(t=3.589, 4.220, 4.359, all P<0.05). After treatment, the levels of ALT, AST, GGT and TBil in the observation group were (39.24±28.37)U/L, (45.18±34.35)U/L, (41.63±10.55)U/L, (20.94±9.15)μmol/L, respectively, which were lower than (85.18±27.22)U/L, (109.25±37.09)U/L, (50.71±9.62)U/L, (33.97±10.11)μmol/L in the control group(t=7.184, 7.818, 3.905, 5.898, all P<0.05). The levels of HBV-DNA in the control group at 6 months and 12 months after treatment were (3.18±1.13) copies/mL and (2.25±0.51) copies/mL, respectively, which were significantly lower than (3.65±1.19)copies/mL before treatment(t=1.811, 6.839; all P<0.05). The levels of HBV-DNA in the observation group at 6 months and 12 months after treatment were (2.96±0.97)copies/mL and (2.07±0.81)copies/mL, respectively, which were significantly lower than (3.70±1.13)copies/mL before treatment(t=3.143, 7.415, all P<0.05).
Conclusion:Guishao Liujunzi decoction combined with entecavir tablets in the treatment of liver cirrhosis with hepatitis B not only can significantly improve the clinical symptoms of patients, but also can help to strengthen the antiviral effect, improve the liver function of patients, which has important significance to the prognosis.
